BTIG initiated coverage of DermTech (NASDAQ:DMTK) with a “buy” rating and $53 price target. The stock closed at $42.05 on April 30. DermTech provides genomic diagnostic testing for various skin diseases and conditions...
William Blair initiated coverage of DermTech (NASDAQ:DMTK) with an “outperform” rating. The stock closed at $11.75 on Oct. 29. Analyst Brian Weinstein writes that DermTech is focused on driving adoption of its non...
Cowen launched coverage of DermTech (NASDAQ:DMTK) with an “outperform” rating and $20 price target. The stock closed at $10.65 on Sept. 9. DermTech provides the only commercial-stage genomics-based non-invasive solution...